For Healthier Babies
As the leader in newborn screening tests and instruments, we deliver solutions that help prevent hundreds of thousands of disabilities and fatalities among children every year. With just a small blood sample at birth, this life-saving technology can detect more than 50 congenital disorders early enough for physicians to administer the treatment necessary to save lives and prevent disabilities. Despite this progress, only about one in three babies worldwide receive newborn screening. That's why PerkinElmer is collaborating with governments and health organizations to make it more accessible around the world.
Newborn Screening Around The World
Innovation in Newborn Screening
Meet Anna Potier, scientist in our Waltham Diagnostics R&D group at PerkinElmer. Anna has used her knowledge of chemistry, mass spectrometry, multi-factor optimization and problem-solving to become an indispensable member of the Lysosomal Storage Disorder, or “LSD,” assay development team. She has been the lead author of several posters and a coauthor on two peer-reviewed publications, with more in the pipeline. In addition, she is the sole inventor on a patent application that is powerfully enabling of multiplex LSD enzyme activity assays.